Maurits Vissers

9PUBLICATIONS
39CO-AUTHORS
Toxicology (incl. clinical toxicology)Molecular targetsPredictive and prognostic markersClinical pharmacology and therapeuticsEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 13, 2026
Interpretation of Chemistry, Hematology and Coagulation Laboratory Results in Early-Phase Clinical Pharmacology Trials; a Retrospective Analysis Based on the Placebo Arm of Randomized-Controlled Trials.

|Aug 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.

Brittany N Flores, Seungyoon B Yu, Isaac V Cohen

|Jun 20, 2024
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.

Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio

|May 13, 2023
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.

Maurits F J M Vissers, Matthew D Troyer, Eva Thijssen

|Feb 22, 2023
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.

Danna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers

|Oct 10, 2022
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.

Manon L M Prins, Johan L van der Plas, Maurits F J M Vissers

Pageof 2

Frequent Collaborators

5 joint publications

Jules A A C Heuberger

3 joint publications

Geert Jan Groeneveld

3 joint publications

Matthew D Troyer

1 joint publications

Joop M A Van Gerven